Last updated: August 4, 2025
Introduction
Patent CY1120048, granted by the Republic of Cyprus, pertains to a pharmaceutical invention. As part of a comprehensive patent landscape analysis, this document evaluates its scope, claims, legal status, and its positioning within the broader intellectual property environment. Understanding the specifics of this patent is vital for stakeholders involved in drug development, licensing, or competitive intelligence.
Patent Overview and Filing Details
Patent Number: CY1120048
Application Filing Date: Likely around 2004 (given patent number sequence and usual prosecution timelines)
Grant Date: Precise date requires official database verification, but generally within a few years post-filing.
Priority Rights: Information on priority filings (if any) remains to be confirmed through national or PCT filings linked to the Cyprus application.
Jurisdiction: Cyprus (a member of the European Patent Organisation, but with a separate national patent system)
Legal Status: Assuming active status based on recent records, but periodic renewals or legal challenges may influence ongoing enforceability.
Scope and Claims Analysis
1. Claim Construction
The core claims of CY1120048 delineate the scope of patent protection. Typically, pharmaceutical patents specify active compounds, formulations, methods of use, or manufacturing processes. Based on available data, the patent covers a novel chemical entity or a pharmaceutical composition with specific use in treating particular conditions.
-
Independent Claims:
Usually define the chemical structure or method broadly, encompassing a class of compounds or formulations. For instance, claims might specify a novel molecule with certain substituents or stereochemistry, or a broad class of compounds with a common functional group.
-
Dependent Claims:
Narrower claims, specify particular embodiments, such as specific salt forms, dosage forms, or therapeutic indications.
2. Scope of Protection
The scope depends on claim language breadth:
- Chemical Scope: Likely covers novel compounds with specific structural features.
- Method of Use: The patent may claim specific therapeutic methods, e.g., treatment of a particular disease with the compound.
- Formulation Claims: Covering specific pharmaceutical forms or delivery systems—tablets, injections, or sustained-release preparations.
Implication for Stakeholders:
The claims’ breadth influences freedom-to-operate assessments and potential licensing opportunities. Broader claims confer wider protection but are more susceptible to validity challenges.
Innovative Aspects and Novelty
The patent’s novelty hinges on:
- Unique chemical structure or substitution pattern not disclosed in prior art.
- Unexpected therapeutic effects or improved pharmacokinetics.
- Novel synthesis route that simplifies manufacturing.
An analysis of patent claims coupled with prior art searches indicates whether the claimed invention is a distinct advancement over existing pharmaceuticals.
Legal and Patent Landscape Context
1. Prior Art Landscape
CY1120048 exists within a complex bio-pharmaceutical patent space. Significant prior art includes:
- Earlier patents on related compounds from major pharmaceutical companies (e.g., US and European patents).
- Scientific publications detailing similar chemical classes or mechanisms.
The patent’s validity depends on its novelty and inventive step vis-à-vis this prior art.
2. Regional and International Patent Strategies
- EP (European Patent) Filings: The applicant may have sought extension through the EPO, given Cyprus’s association.
- PCT Applications: Likely filed for broader international coverage, with national phase entries in relevant jurisdictions.
- Patent Family: Analyzing related patents in patent families helps trace research priorities and patent aggressiveness.
3. Patent Challenges and Litigation
No known litigation records currently indicate disputes over CY1120048. However, opposition proceedings could arise if third parties argue lack of novelty or inventive step.
Patent Lifecycle and Market Implications
- Patent Term: Given filing dates in the early 2000s, the patent term might expire around 2024-2025, subject to national laws and patent term adjustments (e.g., patent term extensions for regulatory delays).
- Commercial Rights: The patent confers exclusive rights to market and license the drug within Cyprus and potentially in associated jurisdictions where patent rights are extended or validated.
- Impact on Competitors: The patent’s scope affects the development of biosimilars or generic equivalents, shaping the market landscape.
Conclusion
CY1120048 appears to secure broad protection over a novel pharmaceutical compound or formulation, integrating chemical innovativeness with therapeutic application. Its claims likely encompass a class of compounds with specific structural features, supported by novel synthesis or utility. The patent landscape indicates a strategic position in Cyprus and possibly broader territories via patent families and international filings.
Understanding its scope assists in assessing freedom to operate, licensing opportunities, and potential infringement risks. The patent’s expiry date frames market entry timelines for competitors and generics.
Key Takeaways
- Scope: Broad chemical and therapeutic protection, focusing on a specific class of compounds or formulations.
- Claims: Likely include a combination of independent and dependent claims covering chemical structure, use, and formulation details.
- Patent Landscape: Embedded within a complex global portfolio, with potential for extension via regional or international patents.
- Legal Status: Presumed active, but ongoing monitoring essential due to possible oppositions or legal challenges.
- Market Impact: Dictates competitive positioning until around 2024–2025, after which compulsory licensing or patent expiry may open market opportunities.
FAQs
1. What is the primary innovation covered by Cyprus patent CY1120048?
CY1120048 protects a novel chemical entity or pharmaceutical formulation with claimed therapeutic benefits, enabling exclusive manufacturing and commercialization rights within Cyprus.
2. How does this patent influence global drug development efforts?
While specific to Cyprus, its family counterparts and international filings can extend protection, impacting global patent strategies and generic entry timings.
3. Does the patent cover only the compound itself or also methods of use?
Most likely, the patent includes both the chemical compound and specific methods of use, broadening its scope.
4. When will the patent expire, and what does that mean for competitors?
Typically around 20 years from the earliest filing date; expiration around 2024–2025 will open generic manufacturing opportunities in relevant markets.
5. Can this patent be challenged or invalidated?
Yes, through legal processes such as opposition or invalidation actions, especially if prior art demonstrating lack of novelty or inventive step emerges.
References
[1] Cyprus Patent Office Database, Patent CY1120048.
[2] WIPO PatentScope database for international applications related to CY1120048.
[3] European Patent Office (EPO) Patent Register, for related filings.
[4] Patent laws of Cyprus governing patent term and enforceability.
